BOTHELL, Wash., July 31, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced that it will report its second quarter 2018 financial and operating results after the close of U.S. financial markets on Tuesday, August 7, 2018. Alder management will host a conference call and live audio webcast with accompanying slides to discuss the results and provide a general business update at 5:00 p.m. ET the same day.
The live call may be accessed by dialing (877) 430-4657 for domestic callers or (484) 756-4339 for international callers and providing conference ID number 9588479. The webcast and accompanying slides can be accessed from the Events & Presentations page of the Investors section of Alder's website at www.alderbio.com and will be available for replay following the call for at least 30 days.
About Alder BioPharmaceuticals, Inc.
Alder BioPharmaceuticals is a clinical-stage biopharmaceutical company focused on transforming the migraine treatment paradigm through the discovery, development and commercialization of novel therapeutic antibodies. Alder’s lead product candidate, eptinezumab, is a pivotal-stage monoclonal antibody (mAb) that inhibits calcitonin gene-related peptide (CGRP). Eptinezumab is currently in late-stage clinical development and, if approved, will be the first-to-market infusion therapy for migraine prevention. Alder is also developing ALD1910, a preclinical mAb that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38) for migraine prevention. For more information, visit www.alderbio.com.
Investor Relations Contacts:
Vice President, Corporate Strategy
Alder Biopharmaceuticals, Inc.
Stern Investor Relations, Inc.
Source: Alder BioPharmaceuticals, Inc.